Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
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
pEhhQLt2vb5eSD82
Listen
